Royalty Pharma

Biotechnology ResearchNew York, United States51-200 Employees

Royalty Pharma, founded in 1996, is a biotechnology research company headquartered in New York City at 110 East 59th Street, 33rd Floor, New York, NY 10022, United States. It is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma builds a portfolio of royalties that entitle it to payments based on top-line sales of many therapies, funding innovation directly by co-funding late-stage clinical trials and new product launches in exchange for future royalties, and indirectly by acquiring royalties from the original innovators. Its current portfolio includes royalties on more than 35 commercial products and 19 development-stage product candidates, including Vertex's Trikafta and Alyftrek, Johnson & Johnson's Tremfya, GSK's Trelegy, Roche's Evrysdi, Servier's Voranigo, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Pfizer's Nurtec ODT, and Gilead's Trodelvy, among others. The company employs between 51 and 200 people and operates within the biotechnology research industry.

Sign up for free to view info

Email Format Employee directory